Fig. 3: Mitigation strategies developed to increase intramyocardial injection therapeutic effectiveness.
a Morphological differences in hPSC-CMs as they progressively matured with palmitate (Pal), Dex and T3 (DT) or PPar agonist + palmitate + Dex and T3 (mature)23. b ECG traces of arrhythmias present in a minipig injury model NSR normal, VT ventricular tachycardia, AJR accelerated junctional rhythm, AIVR accelerated idioventricular82. c Anti-arrhythmia drugs decrease the arrhythmogenic burden in hPSC-CM treated pigs22. d scRNAseq data of hPSC-CMs showing the multiple number of subpopulations contained within one culture22. e Diagram of gene edits made in MEDUSA hPSC-CMs to reduce automaticity. Red channels are knockouts, and green channels were knocked in. f Arrhythmogenic burden was decreased in the gene edited hPSC-CM treatment group81. a Modified from ref. 23 originally published under CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/. b Modified from ref. 82 originally published under CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/. c, d Modified from ref. 22 originally published under CC-BY 4.0. f Reprinted from ref. 81 with permission from Elsevier.
